(Q43695199)

25 November 2017

title

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). (English)

1 reference

positron emission tomography

25 November 2017

main subject

1 reference

G Jerusalem

1

1 reference

25 November 2017

Y Beguin

2

1 reference

25 November 2017

F Najjar

3

1 reference

25 November 2017

R Hustinx

4

1 reference

25 November 2017

M F Fassotte

5

1 reference

25 November 2017

P Rigo

6

1 reference

25 November 2017

G Fillet

7

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

12

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

825-830

1 reference

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

The role of positron emission tomography (PET) in the management of lymphoma patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Hodgkin disease: contributions of chest CT in the initial staging evaluation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Role of67gallium citrate scanning in the management of non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Clinical usefulness of 67gallium scanning in the malignant lymphomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011169332265

7 January 2021

Identifiers

DOI

10.1023/A:1011169332265

1 reference

25 November 2017

1 reference